EU sees 2025 pharma export uptick amid competitiveness concerns
New figures debuted by the European Union (EU) have uncovered a significant rise in the year-on-year value of pharma trade …
Post
-
-
Pharma 5.0, Sustainability & Security: PHARMAP 2026 brings pharma’s future into focus
As the pharmaceutical industry navigates a series of interconnected industry challenges, the pharma community's attention turns to Amsterdam. Later this …
-
Travere Therapeutics gains FDA approval for sparsentan in FSGS
Travere Therapeutics has received the US Food and Drug Administration (FDA) full approval for Filspari (sparsentan) to reduce proteinuria in …
-
Novo Nordisk and OpenAI forge alliance to drive speedy drug development
Novo Nordisk has partnered with tech giant OpenAI to expedite its drug development efforts, as the Danish pharma looks to …
-
MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority
Merck & Co (MSD) and Daiichi Sankyo have received priority review from the US Food and Drug Administration (FDA) for …
-
AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid
AbbVie has cut a deal worth up to $745m with Chinese biopharmaceutical company, Haisco, to bolster its pain pipeline amid …
-
Telix and Regeneron sign $4.3bn deal to co-develop radiopharmaceutical therapies
Telix and Regeneron Pharmaceuticals have entered a partnership worth up to $4.3bn for the development and commercialisation of new radiopharmaceutical …
-
FDA issues complete response letter to Replimune’s RP1 for melanoma
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Replimune Group’s biologics licence application …
-
BMS and Oxford BioTherapeutics join forces in TCE discovery pact
Bristol Myers Squibb (BMS) and Oxford BioTherapeutics (OBT) have forged an alliance to discover and develop new T-cell engager (TCE) …
-
Emerging therapies bring hope for frail HNSCC patients unfit for standard treatment
The number of diagnosed incident cases of head and neck squamous cell carcinoma (HNSCC) are projected to climb from 229,000 …
-
Advancing single-cell transcriptomics into the mainstream of biomedical research
Kelly Parliament, staff application scientist at Beckman Coulter Life Sciences, discusses how automation is improving the efficiency of single-cell transcriptomic …
-
Roche and C4 Therapeutics to advance degrader-antibody conjugates research
Roche has signed a new collaboration agreement with C4 Therapeutics to jointly advance research in the field of degrader-antibody conjugates …
-
Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers
Oncology drug development has shifted decisively towards precision immunotherapies, where biomarker-defined patient populations play a pivotal role. Immuno-oncology now represents …
-
Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation
Gan & Lee Pharmaceuticals has entered an exclusive licence agreement with JW Pharmaceutical for the clinical development, regulatory approval, and …
-
EverSea Medicines to acquire Hasten Biopharmaceuticals
Everest Medicines’ wholly owned subsidiary EverSea Medicines (Singapore) has signed a share purchase agreement to conditionally acquire Hasten Biopharmaceuticals, a …
